2025 GILEAD and LEO PHARMA enters into strategic partnership | LEO …
Jan 11, 2025 · FOSTER CITY, Calif and BALLERUP, Denmark, January 11, 2025 – Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of ...
Gilead Sciences, Inc. - Gilead and LEO Pharma Enter Into Strategic ...
Jan 11, 2025 · Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead and LEO Pharma Enter Into Strategic Partnership to …
Jan 11, 2025 · Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders.
Gilead, LEO Pharma partner to develop programs for …
Jan 11, 2025 · Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.
Gilead, LEO Pharma Enter Strategic Partnership To Accelerate ...
Jan 11, 2025 · (RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of...
Gilead and LEO Pharma Enter Into Strategic Partnership to …
Jan 11, 2025 · Gilead will lead further development efforts for the oral programs, while LEO Pharma will lead development for potential topical formulations of STAT6 inhibitors.
Gilead and LEO link on STAT6 for inflammatory conditions
Jan 13, 2025 · Gilead will acquire LEO Pharma’s preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will spearhead further development of the oral programmes, while LEO Pharma will focus on developing potential …
Gilead and LEO Pharma partner to develop oral STAT6 program
Jan 13, 2025 · Gilead will gain exclusive global rights to develop and commercialize LEO Pharma’s preclinical oral STAT6 program, which includes small molecule inhibitors and targeted protein degraders.
Gilead, LEO Pharma partner to develop programs for …
Jan 11, 2025 · (Reuters) - Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.
Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory ...
Jan 13, 2025 · To develop and market oral STAT6 inhibitors for inflammatory illnesses, Gilead Sciences (GILD, Financials) has teamed up with LEO Pharma for a $1.7 billion investment, the firms said Saturday.
- Some results have been removed